Background
Methods
Study design
Patient material
ID | Age | Sex | Stage | Outcome | Followup | Survival median | Site | WCA | WCA | SCA | SCA | MNA | 11q- | Array platform |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(mo) | (INRGSS) | (mo) | (mo) | (nr) | (average) | (nr) | (average) | |||||||
52* | 4 | m | M | DOD | 10 | adr | 0 | 6 | + | 32K | ||||
55 | 8 | f | M | DOD | 16 | adr | 0 | 6 | + | 32K, Affymetrix | ||||
106* | 10 | f | M | NED | 265 | adr | 0 | 12 | + | 32K | ||||
123* | 11 | f | M | DOD | 3 | adr | 0 | 6 | + | 32K, Affymetrix | ||||
241* | 11 | m | M | DOD | 8 | adr | 1 | 3 | + | 32K, Affymetrix | ||||
244 | 14 | f | M | DOD | 22 | adr | 8 | 2 | + | Affymetrix | ||||
212 | 15 | m | M | DOD | 5 | adr | 0 | 2 | + | 32K, Affymetrix | ||||
240* | 21 | f | M | NED | 43 | adr | 0 | 3 | + | 32K, Affymetrix | ||||
135* | 22 | m | L2 | DOD | 3 | adr | 0 | 3 | + | 32K, Affymetrix | ||||
95* | 26 | f | M | DOD | 15 | adr | 0 | 8 | + | 32K | ||||
238 | 30 | f | M | DOD | 24 | adr | 0 | 6 | + | Affymetrix | ||||
207 | 37 | f | M | DOD | 7 | adr | 2 | 5 | + | 32K, Affymetrix | ||||
217 | 37 | m | M | DOD | 36 | adr | 0 | 8 | + | 32K | ||||
126 | 138 | m | M | DOD | 9 | adr | 0 | 7 | + | 32K, Affymetrix | ||||
MNA
not11q-
|
9.5
|
0.8
|
5.5
| |||||||||||
68 | 41 | m | M | DOD | 12 | adr | 9 | 7 | + | + | 32K, Affymetrix | |||
136* | 48 | f | L2 | DOD | 12 | adr | 1 | 8 | + | + | 32K | |||
MNA & 11q-
|
12.0
|
5.0
|
7.5
| |||||||||||
243 | 32 | f | M | DOD | 28 | adr | 2 | 10 | + | Affymetrix | ||||
149 | 34 | m | M | DOD | 16 | adr | 0 | 12 | + | 32K, Affymetrix | ||||
112 | 40 | m | M | DOD | 18 | adr | 1 | 3 | + | 32K, Affymetrix | ||||
111* | 42 | f | M | NED | 262 | adr | 0 | 7 | + | 32K | ||||
155 | 52 | f | M | DOD | 19 | adr | 3 | 13 | + | 32K, Affymetrix | ||||
32* | 57 | m | M | DOD | 12 | adr | 2 | 15 | + | 32K, Affymetrix | ||||
110 | 60 | m | M | DOD | 12 | adr | 1 | 14 | + | 32K, Affymetrix | ||||
69* | 60 | m | L2 | DOD | 17 | th | 1 | 14 | + | 32K, Affymetrix | ||||
41* | 77 | f | M | DOD | 8 | th | 2 | 15 | + | 32K, Affymetrix | ||||
49 | 82 | m | M | DOD | 14 | adr | 3 | 10 | + | 32K, Affymetrix | ||||
209 | 129 | m | M | DOD | 35 | adr | 2 | 10 | + | 32K, Affymetrix | ||||
229 | 169 | m | L2 | DOD | 34 | adr | 1 | 21 | + | 32K, Affymetrix | ||||
11q-
notMNA
|
16.5
|
1.5
|
12.0
| |||||||||||
107* | 23 | m | M | DOD | 10 | adr | 1 | 2 | 32K, Affymetriix | |||||
131 | 37 | f | L2 | DOD | 21 | adr | 13 | 1 | 32K, Affymetriix | |||||
130 | 46 | m | M | DOD | 57 | adr | 0 | 3 | 32K, Affymetriix | |||||
208 | 59 | m | L2 | DOD | 25 | renal | 4 | 3 | 32K | |||||
242* | 90 | f | M | SD | 37 | th | 12 | 5 | 32K, Affymetriix | |||||
226* | 91 | m | M | SD | 61 | th | 2 | 12 | 32K, Affymetriix | |||||
Not MNA not 11q-
|
23.0
|
5.3
|
4.3
|
Array-based comparative genomic hybridization
Microarray expression data
The Swedish childhood cancer database
Statistical analysis
Results
Identification of two major unfavorable neuroblastoma groups with different genomic signatures
Age dependence of genetic subgroups
High copy number amplicons
Chr Region (Mb) | Cyto-band | Length(Mb) | Genes | Gene Symbols | Group | No of tumors |
---|---|---|---|---|---|---|
chr:2:0.366-0.793 | p25.3 | 0.427 | 1 |
TMEM18
| NMA | 1 |
chr:2:2.304-6.219 | p25.3-p25.2 | 3.915 | 12 |
ADI1, ALLC, COLEC11, LOC150622, LOC400940, LOC730811, MYT1L, RNASEH1, RPS7, SOX11, TSSC1, TTC15
| NMA | 1 |
chr:2:3.605-4.280 | p25.3 | 0.675 | 3 |
ALLC, COLEC11, RPS7
| NMA | 1 |
chr:2:5.708-7.439 | p25.2-p25.1 | 1.731 | 6 |
CMPK2, LOC150622, LOC400940, RNF144A, RSAD2, SOX11
| NMA | 1 |
chr:2:6.372-6.855 | p25.2 | 0.483 | 0 | NMA | 1 | |
chr:2:10.413-11.244 | p25.1 | 0.831 | 10 |
ATP6V1C2, C2orf50, HPCAL1, KCNF1, NOL10,
ODC1
, PDIA6, PQLC3, ROCK2, SNORA80B
| NMA | 2 |
chr:2:11.622-11.878 | p25.1 | 0.256 | 3 |
GREB1, LPIN1, NTSR2
| NMA | 1 |
chr:2:13.097-13.580 | p24.3 | 0.483 | 0 | NMA | 1 | |
chr:2:14.219-14.292 | p24.3 | 0.073 | 0 | NMA | 2 | |
chr:2:15.895-16.095 | p24.3 | 0.200 | 2 |
MYCN
, MYCNOS
| NMA | 16 |
chr:2:16.675-16.705 | p24.3 | 0.030 | 1 |
FAM49A
| NMA | 6 |
chr:2:16.846-17.106 | p24.3-p24.2 | 0.260 | 0 | NMA | 6 | |
chr:2:18.197-18.423 | p24.2 | 0.227 | 0 | NMA | 3 | |
chr:2:20.546-21.012 | p24.1 | 0.466 | 3 |
C2orf43, GDF7, HS1BP3
| NMA | 1 |
chr:2:22.493-25.674 | p24.1-p23.3 | 3.181 | 21 |
ADCY3, ATAD2B, C2orf44, C2orf79, C2orf84, CENPO, DNAJC27, DNMT3A, DTNB, EFR3B, FKBP1B, ITSN2, KLHL29, LOC375190, MFSD2B, NCOA1, PFN4, POMC, SF3B14, TP53I3, UBXN2A
| NMA | 1 |
chr:2:26.853-27.169 | p23.3 | 0.316 | 9 |
AGBL5, C2orf18, CENPA, DPYSL5, EMILIN1, KHK, LOC100128731, MAPRE3, TMEM214
| NMA | 2 |
chr:2:28.022-28.430 | p23.2 | 0.408 | 1 |
BRE
| NMA | 2 |
chr:2:29.071-30.833 | p23.2-p23.1 | 1.762 | 8 |
ALK
, C2orf71, CAPN13, CLIP4, FAM179A, LBH, LCLAT1, YPEL5
| NMA | 2 |
chr:2:38.841-39.010 | p22.1 | 0.168 | 4 |
DHX57, GEMIN6, LOC100271715, MORN2
| NMA | 1 |
chr:2:45.742-46.467 | p21 | 0.725 | 2 |
EPAS1, PRKCE
| NMA | 1 |
chr:2:47.379-47.698 | p21-p16.3 | 0.319 | 3 |
EPCAM, KCNK12, MSH2
| NMA | 1 |
chr:2:48.848-49.512 | p16.3 | 0.664 | 1 |
FSHR
| NMA | 1 |
chr:3:170.768-172.093 | q26.2 | 1.325 | 18 |
ARPM1, CLDN11, EIF5A2, GPR160, LOC100128164, LRRC31, LRRC34, LRRIQ4, MECOM, MYNN, PHC3,
PRKCI
, RPL22L1, SAMD7, SEC62,
SKIL
, SLC7A14, TERC
| NMA | 1 |
chr:3:173.047-173.459 | q26.31 | 0.411 | 2 |
FNDC3B, TMEM212
| NMA | 1 |
chr:11:68.463-69.308 | q13.2-q13.3 | 0.845 | 9 |
CCND1
, FGF19,
FGF4
, IGHMBP2, MRGPRD, MRGPRF, MYEOV, ORAOV1, TPCN2
| Not NMA, not 11q- | 1 |
chr:12:56.182-57.066 | q13.3-q14.1 | 0.884 | 23 |
AGAP2, AVIL, B4GALNT1,
CDK4
, CTDSP2, CYP27B1, DCTN2, DDIT3, DTX3, FAM119B, GEFT, KIF5A, LOC100130776, MARCH9, MARS, MBD6, METTL1, OS9, PIP4K2C, SLC26A10, TSFM, TSPAN31, XRCC6BP1
| Not NMA, not 11q- | 1 |
chr:12:67.060-68.692 | q15 | 1.632 | 13 |
BEST3, CCT2, CPM, CPSF6, FRS2, LRRC10, LYZ,
MDM2
, NUP107, RAB3IP,
RAP1B
, SLC35E3, YEATS4
| Not NMA, not 11q- | 1 |
chr:12:71.578-73.413 | q21.1 | 1.835 | 1 |
LOC552889
| Not NMA, not 11q- | 1 |
chr:12:83.287-83.563 | q21.31 | 0.276 | 0 | Not NMA, not 11q- | 1 | |
chr:12:116.476-116.802 | q24.22-q24.23 | 0.326 | 1 |
KSR2
| Not NMA, not 11q- | 1 |